The Biology of JAK2 Fusions and Getting an Accurate Diagnosis
At a Glance
Doctors confirm a myeloid/lymphoid neoplasm with JAK2 rearrangement by finding a JAK2 gene fusion—often with PCM1, ETV6, or BCR—and combining bone marrow findings with chromosome, gene, and cell-marker tests rather than relying on one test alone.
Getting an accurate diagnosis for this rare disease is a process of genetic detective work. Because it can look like several other types of blood cancer, your medical team must use advanced molecular testing to find the specific “fusion” that is driving the disease [1][2].
The Biology: An Altered Switch
The most common genetic cause of this condition is a translocation known as t(8;9)(p22;p24) [3]. This code means that a piece of chromosome 8 and a piece of chromosome 9 have swapped places. This swap fuses two genes together: PCM1 and JAK2 [4].
Under normal conditions, your JAK2 gene acts like a switch that tells your body to make blood cells only when needed. When it fuses with PCM1 (or other partners like ETV6 or BCR), the switch becomes “constitutively active”—meaning it is permanently stuck in the “on” position [3][5]. This sends a constant signal through a pathway called JAK-STAT, forcing your bone marrow to alter its cell production [5].
Why Accurate Diagnosis is Challenging
This disease is a “chameleon.” Because it can involve different types of blood cells and present in various ways, it is often misidentified as other conditions:
- Hypereosinophilic Syndrome (HES): Many patients have high eosinophil counts, but “idiopathic” HES is only diagnosed when no genetic cause can be found. Finding a JAK2 fusion helps properly classify it [6][7].
- Ph-like ALL: If your disease presents with many “blasts” (immature cells), it may look like Philadelphia-like Acute Lymphoblastic Leukemia. Distinguishing these requires integrated morphology, flow cytometry, cytogenetics, and clinical context—not just one test [2][1].
- Systemic Mastocytosis: This involves different genetic markers (usually KIT D816V). Distinguishing these is vital because treatments differ [8].
The Diagnostic Checklist
To confirm this diagnosis, your pathology report is built from complementary tests. The treating laboratory chooses the appropriate validated assays [9].
| Test Type | What it Looks For | Why it Matters |
|---|---|---|
| Bone Marrow Biopsy | Cell shapes, counts, and fibrosis (scarring). | Identifies if the disease is chronic or acute and checks for marrow damage [10][1]. |
| Karyotyping | Large-scale changes in chromosomes (like the t(8;9) swap). | Provides the first clue that a rearrangement has occurred [11]. |
| FISH (Fluorescence In Situ Hybridization) | Uses glowing probes to find genetic breaks. | Can find rearrangements that are “cryptic” or invisible to standard karyotyping [12][13]. |
| RNA/DNA Sequencing & PCR | Reads the actual genetic sequence or transcripts. | The most precise way to identify the exact partner gene (PCM1, ETV6, BCR, etc.) [14][15]. |
| Flow Cytometry | The “fingerprint” of the proteins on the surface of your cells. | Determines cell phenotypes and lineages [9]. |
Confirming the specific partner gene (like PCM1, ETV6, or BCR) helps classify the disease, though predicting individual responses is challenging [16][17].
Common questions in this guide
What does a JAK2 fusion mean in this blood disorder?
Which tests are used to diagnose a JAK2 rearrangement?
Can a JAK2 fusion be mistaken for another blood condition?
Why might karyotyping miss a JAK2 rearrangement?
What should I ask about my JAK2 pathology report?
Get notified when new evidence is published on Myeloid/lymphoid neoplasm associated with JAK2 rearrangement.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (17)
- 1
Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.
Tang G, Sydney Sir Philip JK, Weinberg O, et al.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019; (32(4)):490-498 doi:10.1038/s41379-018-0165-9.
PMID: 30401948 - 2
The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and ZBTB20-JAK2 gene fusion presenting as B-lymphoblastic leukemia.
Lee WY, Pfau RB, Choi SM, et al.
Cold Spring Harbor molecular case studies 2020; (6(2)) doi:10.1101/mcs.a004937.
PMID: 32238402 - 3
Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1-JAK2 positive myeloid sarcoma and acute B-lymphoblastic leukemia.
Rizzuto G, Leoncin M, Imbergamo S, et al.
Clinical case reports 2022; (10(1)):e05212 doi:10.1002/ccr3.5212.
PMID: 35028141 - 4
Sustained Response to Ruxolitinib of Eosinophilia-Associated Myeloproliferative Neoplasm with Translocation t(8;9)(p21;p24).
Cai P, Liu S, Duan L, et al.
Acta haematologica 2023; (146(5)):397-400 doi:10.1159/000510281.
PMID: 37562364 - 5
PCM1::JAK2 fusion associates with an atypical form of mycosis fungoides.
Rodriguez-Sevilla JJ, Salido M, Rodriguez-Rivera M, et al.
Virchows Archiv : an international journal of pathology 2022; (481(6)):967-973 doi:10.1007/s00428-022-03372-x.
PMID: 35786767 - 6
Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort.
Metzgeroth G, Steiner L, Naumann N, et al.
Leukemia 2023; (37(9)):1860-1867 doi:10.1038/s41375-023-01958-1.
PMID: 37454239 - 7
World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
Shomali W, Gotlib J
American journal of hematology 2019; (94(10)):1149-1167 doi:10.1002/ajh.25617.
PMID: 31423623 - 8
Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis.
Gotlib J
Current hematologic malignancy reports 2015; (10(4)):351-61 doi:10.1007/s11899-015-0280-3.
PMID: 26404639 - 9
Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics.
Nann D, Fend F
Cancers 2021; (13(14)) doi:10.3390/cancers13143528.
PMID: 34298741 - 10
World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W, Gotlib J
American journal of hematology 2022; (97(1)):129-148 doi:10.1002/ajh.26352.
PMID: 34533850 - 11
BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia.
He R, Greipp PT, Rangan A, et al.
Cancer genetics 2016; (209(5)):223-8.
PMID: 27134074 - 12
Integrated genomic analysis using chromosomal microarray, fluorescence in situ hybridization and mate pair analyses: Characterization of a cryptic t(9;22)(p24.1;q11.2)/BCR-JAK2 in myeloid/lymphoid neoplasm with eosinophilia.
Snider JS, Znoyko I, Lindsey KG, et al.
Cancer genetics 2020; (246-247()):44-47 doi:10.1016/j.cancergen.2020.08.004.
PMID: 32827877 - 13
Identification of STRBP as a Novel JAK2 Fusion Partner Gene in a Young Adult With Philadelphia Chromosome-Like B-Lymphoblastic Leukemia.
Zhang XY, Dai HP, Li Z, et al.
Frontiers in oncology 2020; (10()):611467 doi:10.3389/fonc.2020.611467.
PMID: 33505919 - 14
Next-generation sequencing RNA fusion panel for the diagnosis of haematological malignancies.
Ngo TQ, Goh AFN, Dorwal P, et al.
Pathology 2025; (57(3)):340-347 doi:10.1016/j.pathol.2024.09.009.
PMID: 39672769 - 15
How I diagnose and treat myeloid/lymphoid neoplasms with tyrosine kinase gene fusions.
Reiter A, Metzgeroth G, Cross NCP
Blood 2025; (145(16)):1758-1768 doi:10.1182/blood.2023022417.
PMID: 39046810 - 16
PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature.
Kaplan HG, Jin R, Bifulco CB, et al.
The oncologist 2022; (27(8)):e661-e670 doi:10.1093/oncolo/oyac072.
PMID: 35472244 - 17
Combined Ruxolitinib and Venetoclax Treatment in a Patient with a BCR-JAK2 Rearranged Myeloid Neoplasm.
Lap CJ, Nassereddine S, Liu ML, et al.
Case reports in hematology 2021; (2021()):2348977 doi:10.1155/2021/2348977.
PMID: 34367701
This page is for informational purposes only and does not constitute medical advice. Your hematologist and pathologist should interpret your molecular and bone marrow results in the context of your full evaluation.